Anti-Human ErbB2/Her2 Reference Antibody (NM-02, RUO) (HY286576)

Name: Anti-Human ErbB2/Her2 Reference Antibody (NM-02, RUO)
Brand: abinScience
SKU: HY286576
Price: 370 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.

HY286576

Species reactivity

Human

Applications

ELISA, Bioactivity: FCM, Functional assay, Research in vivo

Host species

Alpaca

Clonality

Monoclonal

Isotype

VHH-His

Clone ID

NM-02

Target

CD340, EC:2.7.10.1, ERBB2, HER2, MLN 19, MLN19, Metastatic lymph node gene 19 protein, NEU, NGL, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Receptor tyrosine-protein kinase erbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2

Endotoxin level

< 10 EU/mg

Purity

>95% as determined by SDS-PAGE.

Purification

Purified by Nickel column

Accession

P04626

Form

Liquid

Storage buffer

0.01M PBS pH 7.4.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information

Application	Dilution
ELISA	1:2000-1:20000

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Alternate Names

NM-02, NM02, NM02

Background

Receptor tyrosine-protein kinase erbB-2 (CD340/ERBB2) is a ~137 kDa protein. Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. CD340 is the therapeutic target of trastuzumab (Herceptin) and trastuzumab deruxtecan (Enhertu).

References

1. Sawmynaden K, et al. Co-crystallisation and humanisation of an anti-HER2 single-domain antibody as a theranostic tool. PLoS One. 2023 Jul 17;18(7):e0288259. [HY286576]

Note

For research use only. Not suitable for clinical or therapeutic use.

Images

References

Datasheet